Skip to main content
Erschienen in: Medical Oncology 10/2016

01.10.2016 | Original Paper

Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up

verfasst von: Daniela Luvero, Francesco Plotti, Alessia Aloisi, Stella Capriglione, Roberto Ricciardi, Andrea Miranda, Salvatore Lopez, Giuseppe Scaletta, Giovanna De Luca, Pierluigi Benedetti-Panici, Roberto Angioli

Erschienen in: Medical Oncology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

We report the long-term follow-up in patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy (NACT) + radical surgery (RS) + adjuvant chemotherapy (ACT) analyzing prognostic factors which may more influence, in a long time, the survival outcome using univariate and multivariate analysis. In this study, we included all patients with diagnosis of locally advanced cervical cancer (IB2-IIB) treated with NACT + RS + ACT from June 2000 and February 2007 as previously described by Angioli et al. (Gynecol Oncol 127(2):290–6, 2012). The primary end-point of the study was overall survival (OS) in patients with node metastases and in those without positive lymph nodes at the end of 10-year follow-up in order to confirm the prognostic role of nodes involvement for a long period. Moreover, we analyzed the impact of other prognostic factors, such as histotype, tumor size, grading and parametrial invasion. Secondary end-point was evaluated in the subgroup of patients with positive nodes the following prognostic factors: number of positive lymph nodes and site of positive lymph nodes. In the subgroup of patients with positive nodes, the OS was 63 %, and in that with negative nodes, the OS was 75 %. On multivariate analysis, the number of nodal metastases, parametrial involvement, grading and the lesion diameter were noted to be significant factors in determining OS. Neither the histotype nor the lymph nodal site is related to survival. Results suggest that CT alone may be an alternative postoperative therapy for patients with cervical cancer.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, et al. (2012) GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC cancer Base No. 11. Lyon, France: International Agency for Research [on-line]. http://globocan.iarc.fr. Ferlay J, Soerjomataram I, Ervik M, et al. (2012) GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC cancer Base No. 11. Lyon, France: International Agency for Research [on-line]. http://​globocan.​iarc.​fr.
2.
Zurück zum Zitat Peters WA III, Liu PY, Barrett R, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.PubMed Peters WA III, Liu PY, Barrett R, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.PubMed
3.
Zurück zum Zitat Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.CrossRefPubMed Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.CrossRefPubMed
4.
Zurück zum Zitat Keys HM, Bundy BN, Stehman FB, et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: a randomized trial of the Gynecology Oncology Group. N Engl J Med. 1999;340:1154–61.CrossRefPubMed Keys HM, Bundy BN, Stehman FB, et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: a randomized trial of the Gynecology Oncology Group. N Engl J Med. 1999;340:1154–61.CrossRefPubMed
5.
Zurück zum Zitat Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002;20(1):179–88.CrossRefPubMed Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002;20(1):179–88.CrossRefPubMed
6.
Zurück zum Zitat Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based chemoradiation improves progression-free survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. N Engl J Med. 1999;340:1144–53.CrossRefPubMed Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based chemoradiation improves progression-free survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. N Engl J Med. 1999;340:1144–53.CrossRefPubMed
7.
Zurück zum Zitat Wong LC, Ngan HYS, Cheung ANY, et al. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol. 1999;17:2055–60.PubMed Wong LC, Ngan HYS, Cheung ANY, et al. Chemoradiation and adjuvant chemotherapy in cervical cancer. J Clin Oncol. 1999;17:2055–60.PubMed
8.
Zurück zum Zitat Roberts KB, Urdaneta N, Vera R, et al. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer. 2000;90:206–23.CrossRefPubMed Roberts KB, Urdaneta N, Vera R, et al. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer. 2000;90:206–23.CrossRefPubMed
9.
Zurück zum Zitat Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966–72.CrossRefPubMed Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966–72.CrossRefPubMed
10.
Zurück zum Zitat Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2010;(1):CD007406. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2010;(1):CD007406.
11.
Zurück zum Zitat Sardi J, Sananes C, Giaroli A, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Cancer. 1998;8:441–50.CrossRef Sardi J, Sananes C, Giaroli A, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Cancer. 1998;8:441–50.CrossRef
12.
Zurück zum Zitat Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol. 2008;110(3):308–15.CrossRefPubMed Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol. 2008;110(3):308–15.CrossRefPubMed
13.
Zurück zum Zitat Cho YH, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer. J Gynecol Oncol. 2009;20(1):22–7.CrossRefPubMedPubMedCentral Cho YH, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer. J Gynecol Oncol. 2009;20(1):22–7.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E. O’Connor D Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007;106(2):362–9 Epub 2007 May 9.CrossRefPubMed Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E. O’Connor D Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007;106(2):362–9 Epub 2007 May 9.CrossRefPubMed
15.
Zurück zum Zitat Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, Dell’anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol. 2009;20(4):660–5.CrossRefPubMed Lissoni AA, Colombo N, Pellegrino A, Parma G, Zola P, Katsaros D, Chiari S, Buda A, Landoni F, Peiretti M, Dell’anna T, Fruscio R, Signorelli M, Grassi R, Floriani I, Fossati R, Torri V, Rulli E. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study. Ann Oncol. 2009;20(4):660–5.CrossRefPubMed
16.
Zurück zum Zitat Sardi J, Sananes C, Giaroli A, Maya G, di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol. 1990;38(3):486–93.CrossRefPubMed Sardi J, Sananes C, Giaroli A, Maya G, di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol. 1990;38(3):486–93.CrossRefPubMed
17.
Zurück zum Zitat Tattersall MHN, Amirez C, Oppleson M. A Randomized trial of adjuvant chemotherapy after radical hysterectomy in stage lb-lla cervical cancer patients with pelvic lymph node metastases. Gynaec Oncol. 1992;46:176–81.CrossRef Tattersall MHN, Amirez C, Oppleson M. A Randomized trial of adjuvant chemotherapy after radical hysterectomy in stage lb-lla cervical cancer patients with pelvic lymph node metastases. Gynaec Oncol. 1992;46:176–81.CrossRef
18.
Zurück zum Zitat Mossa B, Mossa S, Marziani R. Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node Stage IB/IIA cervical cancer. Eur J Gynaec Oncol. 2010;31(5):545–50. Mossa B, Mossa S, Marziani R. Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node Stage IB/IIA cervical cancer. Eur J Gynaec Oncol. 2010;31(5):545–50.
19.
Zurück zum Zitat Takeshima Nobuhiro, Umayahara Kenji, Fujiwara Kiyoshi, Hirai Yasuo, Takizawa Ken. Katsuhiko Hasumi treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB–IIA cervical cancer. Gynecol Oncol. 2006;103(2):618–22 Epub 2006 Jun 14.CrossRefPubMed Takeshima Nobuhiro, Umayahara Kenji, Fujiwara Kiyoshi, Hirai Yasuo, Takizawa Ken. Katsuhiko Hasumi treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB–IIA cervical cancer. Gynecol Oncol. 2006;103(2):618–22 Epub 2006 Jun 14.CrossRefPubMed
20.
Zurück zum Zitat Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol. 1999;73(2):177–83.CrossRefPubMed Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol. 1999;73(2):177–83.CrossRefPubMed
21.
Zurück zum Zitat Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol. 1975;46:507–10.PubMed Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol. 1975;46:507–10.PubMed
22.
Zurück zum Zitat Fuller AF, Elliott N, Kosloff C, Lewis JL. Lymph node metastases from carcinoma of the cervix, stages IB and IIA: implications for prognosis and treatment. Gynecol Oncol. 1982;13:165–74.CrossRefPubMed Fuller AF, Elliott N, Kosloff C, Lewis JL. Lymph node metastases from carcinoma of the cervix, stages IB and IIA: implications for prognosis and treatment. Gynecol Oncol. 1982;13:165–74.CrossRefPubMed
23.
24.
Zurück zum Zitat Mendenhall WM, Thar TL, Bova FJ, Marsuc RB, Morgan LS, Million RR. Prognostic and treatment factors affecting pelvic control of Stage Ib-IIa-b carcinoma of the intact uterine cervix treated with radiation alone. Cancer. 1984;53:2649–54.CrossRefPubMed Mendenhall WM, Thar TL, Bova FJ, Marsuc RB, Morgan LS, Million RR. Prognostic and treatment factors affecting pelvic control of Stage Ib-IIa-b carcinoma of the intact uterine cervix treated with radiation alone. Cancer. 1984;53:2649–54.CrossRefPubMed
25.
Zurück zum Zitat Thar TL, Million RR, Daly JW. Radiation treatment of carcinoma of the cervix. Semin Oncol. 1982;9:299–311.PubMed Thar TL, Million RR, Daly JW. Radiation treatment of carcinoma of the cervix. Semin Oncol. 1982;9:299–311.PubMed
26.
Zurück zum Zitat Van Nagell JR, Rayburn W, Donaldson ES. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix. Cancer. 1979;44:2354–61.CrossRefPubMed Van Nagell JR, Rayburn W, Donaldson ES. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix. Cancer. 1979;44:2354–61.CrossRefPubMed
27.
Zurück zum Zitat Boyce J, Fruchter RO, Nicasti AD, Amliavegar PC, Reinis MS, Nelson JH. Prognostic factors in Stage I carcinoma of the cervix. Gynecol Oncol. 1981;12:154–65.CrossRefPubMed Boyce J, Fruchter RO, Nicasti AD, Amliavegar PC, Reinis MS, Nelson JH. Prognostic factors in Stage I carcinoma of the cervix. Gynecol Oncol. 1981;12:154–65.CrossRefPubMed
28.
Zurück zum Zitat Chung CK, Nahhas WS, Stryker JA, Curry SL, Abt AB, Mortel R. Analysis of factors contributing to treatment failures in Stages Ib and IIa carcinoma of the cervix. Am J Obstet Gynecol. 1980;l38:550–6.CrossRef Chung CK, Nahhas WS, Stryker JA, Curry SL, Abt AB, Mortel R. Analysis of factors contributing to treatment failures in Stages Ib and IIa carcinoma of the cervix. Am J Obstet Gynecol. 1980;l38:550–6.CrossRef
29.
Zurück zum Zitat Chung CK, Stryker JA, Ward SP, Nahhas WA, Mortel R. Histologic grade and prognosis of carcinoma of the cervix. Obstet Gynecol. 1981;57:636–42.PubMed Chung CK, Stryker JA, Ward SP, Nahhas WA, Mortel R. Histologic grade and prognosis of carcinoma of the cervix. Obstet Gynecol. 1981;57:636–42.PubMed
30.
Zurück zum Zitat Perez CA, Breaux S, Madoc-Jones H, Bedeomek TM, Camel HM, Purdy JA, Walz BJ. Radiation therapy alone in the treatment of carcinoma of uterine cervix. 1. Analysis of tumour recurrence. Cancer. 1983;51:1393–402.CrossRefPubMed Perez CA, Breaux S, Madoc-Jones H, Bedeomek TM, Camel HM, Purdy JA, Walz BJ. Radiation therapy alone in the treatment of carcinoma of uterine cervix. 1. Analysis of tumour recurrence. Cancer. 1983;51:1393–402.CrossRefPubMed
31.
Zurück zum Zitat Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. JCO. 2008;26:5802–12.CrossRef Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. JCO. 2008;26:5802–12.CrossRef
32.
Zurück zum Zitat Angioli R, Plotti F, Montera R, Aloisi A, Luvero D, Capriglione S, Terranova C, De Cicco Nardone C, Muzii L, Benedetti-Panici P. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2012;127(2):290–6.CrossRefPubMed Angioli R, Plotti F, Montera R, Aloisi A, Luvero D, Capriglione S, Terranova C, De Cicco Nardone C, Muzii L, Benedetti-Panici P. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2012;127(2):290–6.CrossRefPubMed
33.
Zurück zum Zitat Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.CrossRefPubMed Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.CrossRefPubMed
34.
Zurück zum Zitat Hosaka Masayoshi, Watari Hidemichi, Takeda Mahito, Moriwaki Masashi, Hara Yoko, Todo Yukiharu, Ebina Yasuhiko, Sakuragi Noriaki. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy. J. Obstet. Gynaecol. Res. 2008;34(4):552–6.CrossRefPubMed Hosaka Masayoshi, Watari Hidemichi, Takeda Mahito, Moriwaki Masashi, Hara Yoko, Todo Yukiharu, Ebina Yasuhiko, Sakuragi Noriaki. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy. J. Obstet. Gynaecol. Res. 2008;34(4):552–6.CrossRefPubMed
35.
Zurück zum Zitat Angioli R, Luvero D, Aloisi A, Capriglione S, Gennari P, Linciano F, Li Destri M, Scaletta G, Montera R, Plotti F. Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature. Expert Rev Anticancer Ther. 2014;14(4):431–9.CrossRefPubMed Angioli R, Luvero D, Aloisi A, Capriglione S, Gennari P, Linciano F, Li Destri M, Scaletta G, Montera R, Plotti F. Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature. Expert Rev Anticancer Ther. 2014;14(4):431–9.CrossRefPubMed
36.
Zurück zum Zitat Sardi J, Giaroli A, Sananes C, et al. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma of the cervix uteri: an unexpected therapeutic management. Int J Gynecol Cancer. 1996;6:85–93.CrossRef Sardi J, Giaroli A, Sananes C, et al. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma of the cervix uteri: an unexpected therapeutic management. Int J Gynecol Cancer. 1996;6:85–93.CrossRef
37.
Zurück zum Zitat Dische S. Radiotherapy of cervical cancer. Clin Obstet Gynaecol. 1985;12:203–27.PubMed Dische S. Radiotherapy of cervical cancer. Clin Obstet Gynaecol. 1985;12:203–27.PubMed
38.
Zurück zum Zitat Barter JF, Soong SJ, Shingleton HM, Hatch KD, Orr JW Jr. Complications of combined radical hysterectomy—postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol. 1989;32:292–6.CrossRefPubMed Barter JF, Soong SJ, Shingleton HM, Hatch KD, Orr JW Jr. Complications of combined radical hysterectomy—postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol. 1989;32:292–6.CrossRefPubMed
39.
Zurück zum Zitat Monk BJ, Cha DS, Walker JL, Burger RA, Ramsinghani NS, Manetta A, et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecol Oncol. 1994;54:4–9.CrossRefPubMed Monk BJ, Cha DS, Walker JL, Burger RA, Ramsinghani NS, Manetta A, et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecol Oncol. 1994;54:4–9.CrossRefPubMed
40.
Zurück zum Zitat Morrow PC. Panel report. Is pelvic radiation beneficial in the postoperative management of Stage IB squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? Gynecol Oncol. 1980;10:105.CrossRef Morrow PC. Panel report. Is pelvic radiation beneficial in the postoperative management of Stage IB squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? Gynecol Oncol. 1980;10:105.CrossRef
41.
Zurück zum Zitat Angioli R, Plotti F, Aloisi A, Scaletta G, Capriglione S, Luvero D, Fiore L, Terranova C, Montera R, Panici PB. A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. Gynecol Oncol. 2015;139(3):433–8.CrossRefPubMed Angioli R, Plotti F, Aloisi A, Scaletta G, Capriglione S, Luvero D, Fiore L, Terranova C, Montera R, Panici PB. A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. Gynecol Oncol. 2015;139(3):433–8.CrossRefPubMed
Metadaten
Titel
Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up
verfasst von
Daniela Luvero
Francesco Plotti
Alessia Aloisi
Stella Capriglione
Roberto Ricciardi
Andrea Miranda
Salvatore Lopez
Giuseppe Scaletta
Giovanna De Luca
Pierluigi Benedetti-Panici
Roberto Angioli
Publikationsdatum
01.10.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 10/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0830-0

Weitere Artikel der Ausgabe 10/2016

Medical Oncology 10/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.